{"id":"chloroquine-cq","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nausea and gastrointestinal disturbance"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Pruritus"},{"rate":"1-5","effect":"Retinopathy (with prolonged use)"},{"rate":"0.1-1","effect":"Cardiomyopathy (rare, with high doses)"},{"rate":"0.1-1","effect":"Agranulocytosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chloroquine enters the parasitic food vacuole and binds to heme, preventing its detoxification into hemozoin. This causes accumulation of toxic heme that damages the parasite's cell membrane and leads to cell lysis. The drug also has immunomodulatory properties, including inhibition of toll-like receptor signaling and reduction of inflammatory cytokine production.","oneSentence":"Chloroquine is a quinoline antimalarial that accumulates in parasitic food vacuoles and inhibits heme polymerization, causing toxic heme accumulation and parasite death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:07.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria (treatment and prophylaxis)"},{"name":"Lupus erythematosus"},{"name":"Rheumatoid arthritis"},{"name":"Amebiasis"}]},"trialDetails":[{"nctId":"NCT07430592","phase":"PHASE2","title":"This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"R. Kiplin Guy","startDate":"2026-03-20","conditions":"Malaria, Malaria Vivax, Radical Cure","enrollment":104},{"nctId":"NCT06083688","phase":"PHASE4","title":"Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-10-14","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":1000},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT06666491","phase":"PHASE3","title":"An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Malaria, Vivax","enrollment":300},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax Malaria","enrollment":606},{"nctId":"NCT00131703","phase":"PHASE3","title":"Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2003-03","conditions":"Malaria, Pregnancy","enrollment":900},{"nctId":"NCT04349371","phase":"PHASE2","title":"Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-04-21","conditions":"COVID, Coronavirus Infection","enrollment":5},{"nctId":"NCT03503058","phase":"PHASE2","title":"Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2022-05-07","conditions":"Malaria","enrollment":345},{"nctId":"NCT04079621","phase":"PHASE4","title":"Short Course Radical Cure of P. Vivax Malaria in Nepal","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2021-10-27","conditions":"Malaria, Malaria, Vivax, Malaria,Falciparum","enrollment":27},{"nctId":"NCT02432417","phase":"PHASE2","title":"The Addition of Chloroquine to Chemoradiation for Glioblastoma,","status":"WITHDRAWN","sponsor":"Maastricht Radiation Oncology","startDate":"2023-11-10","conditions":"Glioblastoma, Astrocytoma, Grade IV","enrollment":""},{"nctId":"NCT06044805","phase":"PHASE4","title":"Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax","status":"COMPLETED","sponsor":"Dinka Dugassa","startDate":"2022-12-19","conditions":"Efficacy, Malaria, Chloroquine","enrollment":100},{"nctId":"NCT05980156","phase":"PHASE4","title":"Comparing Chemoprevention Drugs for School-based Malaria Control","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2023-02-13","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":646},{"nctId":"NCT03208907","phase":"PHASE3","title":"DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2018-07-05","conditions":"Malaria, Vivax, Therapeutics","enrollment":419},{"nctId":"NCT01650558","phase":"NA","title":"Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-11","conditions":"HIV","enrollment":1499},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT04342650","phase":"PHASE2","title":"Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2020-04-08","conditions":"COVID-19, SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia","enrollment":152},{"nctId":"NCT04351191","phase":"PHASE4","title":"PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","status":"TERMINATED","sponsor":"Government of Punjab, Specialized Healthcare and Medical Education Department","startDate":"2020-04-15","conditions":"Sars-CoV2, Symptomatic Condition, Covid-19","enrollment":137},{"nctId":"NCT00323375","phase":"PHASE1","title":"Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine","status":"COMPLETED","sponsor":"Tulane University Health Sciences Center","startDate":"1999-08-01","conditions":"Malaria","enrollment":122},{"nctId":"NCT02563496","phase":"PHASE2","title":"A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-06","conditions":"Malaria, Vivax","enrollment":60},{"nctId":"NCT04241705","phase":"NA","title":"Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia","status":"UNKNOWN","sponsor":"Armauer Hansen Research Institute, Ethiopia","startDate":"2020-01-20","conditions":"Malaria","enrollment":48960},{"nctId":"NCT03278808","phase":"PHASE2","title":"Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis","status":"WITHDRAWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2018-09-17","conditions":"Malaria","enrollment":""},{"nctId":"NCT02773979","phase":"PHASE1","title":"PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-12","conditions":"Plasmodium Falciparum Infection","enrollment":28},{"nctId":"NCT00969306","phase":"PHASE1","title":"Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients","status":"TERMINATED","sponsor":"Maastricht Radiation Oncology","startDate":"2013-09","conditions":"Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT03400865","phase":"NA","title":"Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-10-25","conditions":"Resistance, Disease, Prolactinoma","enrollment":30},{"nctId":"NCT02216123","phase":"PHASE3","title":"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-30","conditions":"Malaria, Vivax","enrollment":251},{"nctId":"NCT02698748","phase":"PHASE2, PHASE3","title":"Evaluating the Role of Chloroquine for Malaria Elimination","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2015-01","conditions":"Malaria","enrollment":75},{"nctId":"NCT01575782","phase":"PHASE1","title":"Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Maastricht Radiation Oncology","startDate":"2014-05","conditions":"Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT02511054","phase":"PHASE1","title":"Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-21","conditions":"Malaria","enrollment":57},{"nctId":"NCT01205178","phase":"PHASE1","title":"G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-02","conditions":"Malaria","enrollment":192},{"nctId":"NCT02115516","phase":"PHASE1","title":"Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":67},{"nctId":"NCT01728701","phase":"PHASE1","title":"Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2012-09","conditions":"Malaria, Plasmodium Falciparum","enrollment":30},{"nctId":"NCT01716260","phase":"","title":"Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-01","conditions":"Vivax Malaria","enrollment":24},{"nctId":"NCT02691910","phase":"PHASE2, PHASE3","title":"Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2014-08","conditions":"Malaria, Vivax","enrollment":204},{"nctId":"NCT02550964","phase":"","title":"Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-01","conditions":"Toxic Maculopathy","enrollment":124},{"nctId":"NCT01727531","phase":"NA","title":"IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy","status":"COMPLETED","sponsor":"Main Line Health","startDate":"2008-12","conditions":"Brain Metastasis","enrollment":20},{"nctId":"NCT01103713","phase":"PHASE3","title":"Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-03","conditions":"Asymptomatic Parasitemia In Pregnancy","enrollment":168},{"nctId":"NCT01783340","phase":"PHASE1, PHASE2","title":"Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis","status":"WITHDRAWN","sponsor":"Radboud University Medical Center","startDate":"2013-04","conditions":"Malaria, Falciparum","enrollment":""},{"nctId":"NCT00379821","phase":"PHASE3","title":"Chloroquine Alone or in Combination for Malaria in Children in Malawi","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-02","conditions":"Plasmodium Falciparum Infection","enrollment":640},{"nctId":"NCT01784315","phase":"","title":"Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria","status":"UNKNOWN","sponsor":"Ministry of Health, Bhutan","startDate":"2013-03","conditions":"Parasitemia","enrollment":50},{"nctId":"NCT01378286","phase":"PHASE3","title":"Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Malaria","enrollment":380},{"nctId":"NCT01218932","phase":"PHASE1","title":"Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-10","conditions":"Vivax Malaria","enrollment":16},{"nctId":"NCT00680732","phase":"PHASE4","title":"Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2003-06","conditions":"Malaria, Malaria in Pregnancy","enrollment":1370},{"nctId":"NCT00730366","phase":"PHASE3","title":"New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2004-03","conditions":"Malaria in Pregnancy","enrollment":2766},{"nctId":"NCT01100060","phase":"PHASE1","title":"A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-04","conditions":"Malaria Prophylaxis","enrollment":40},{"nctId":"NCT00964691","phase":"PHASE4","title":"A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands","status":"TERMINATED","sponsor":"Ministry of Health and Medical Services, Solomon Islands","startDate":"2009-08","conditions":"Malaria, Malaria in Pregnancy","enrollment":2504},{"nctId":"NCT01019408","phase":"PHASE4","title":"Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"1993-11","conditions":"Malaria, Falciparum","enrollment":163},{"nctId":"NCT00959517","phase":"PHASE2","title":"Trial of Artesunate Combination Therapy in Pakistan","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2001-07","conditions":"Uncomplicated Falciparum Malaria","enrollment":588},{"nctId":"NCT00399074","phase":"PHASE3","title":"Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia","status":"COMPLETED","sponsor":"Makerere University","startDate":"2006-10","conditions":"Sickle Cell Anemia, Malaria","enrollment":220},{"nctId":"NCT00118807","phase":"PHASE3","title":"Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2003-08","conditions":"Malaria","enrollment":1800},{"nctId":"NCT00176072","phase":"","title":"BlueCQ Bioavailability","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2004-08","conditions":"Methylene Blue, Chloroquine, Pharmacokinetics","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2892,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CQ","Aralen"],"phase":"marketed","status":"active","brandName":"Chloroquine (CQ)","genericName":"Chloroquine (CQ)","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chloroquine is a quinoline antimalarial that accumulates in parasitic food vacuoles and inhibits heme polymerization, causing toxic heme accumulation and parasite death. Used for Malaria (treatment and prophylaxis), Lupus erythematosus, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1949-10-31T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":"ARALEN","application_number":"NDA006002"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}